Fig. 5

Upregulation of ABCG1 via alterations in Wnt/β-catenin signaling contributes to the effects of saracatinib on oxaliplatin resistance of HCC cells. (A) Immunoblotting was used to examine the expression of ABCG1 following Wnt/β-catenin signaling pathway inhibition by KYA1797K. (B) Wnt/β-catenin signaling pathway and PCNA expression was determined following silencing of ABCG1 by siRNA and restoration treatment in HCC cells. (C) The sensitivity of HCC cells to oxaliplatin was measured as IC₅₀ following silencing of ABCG1 expression with siRNA or mock siRNA treatment. (D) The sensitivity of cells to oxaliplatin following treatment with the Wnt signaling inhibitor KYA1797K was determined as IC₅₀ values. (E ) Interference with ABCG1 expression resulted in reversal of the saracatinib-induced oxaliplatin resistance with smaller subcutaneous xenografts